United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by True Wealth Design LLC

True Wealth Design LLC lessened its stake in United Therapeutics Co. (NASDAQ:UTHR) by 95.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 169 shares of the biotechnology company’s stock after selling 3,274 shares during the quarter. True Wealth Design LLC’s holdings in United Therapeutics were worth $61,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. ClariVest Asset Management LLC boosted its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter worth about $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at about $33,000. USA Financial Formulas purchased a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Brooklyn Investment Group acquired a new position in United Therapeutics in the 3rd quarter worth about $33,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $370.49 on Friday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The firm has a market capitalization of $16.54 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The stock’s fifty day moving average is $367.77 and its two-hundred day moving average is $335.19.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the firm posted $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now directly owns 3,675 shares in the company, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 127,227 shares of company stock worth $47,398,820 in the last 90 days. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.